Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with (90)Y-Ibritumomab Tiuxetan or (131)I-Tositumomab

This study aimed at identifying clinical factors for predicting hematologic toxicity after radioimmunotherapy with (90)Y-ibritumomab tiuxetan or (131)I-tositumomab in clinical practice. METHODS: Hematologic data were available from 14 non-Hodgkin lymphoma patients treated with (90)Y-ibritumomab tiux...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Baechler, Sébastien, Hobbs, Robert F., Jacene, Heather A., Bochud, François O., Wahl, Richard L., Sgouros, George
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3169802/
https://ncbi.nlm.nih.gov/pubmed/21098795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.110.079947
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars